Skip to content

Eidos Therapeutics, Inc.

Delisted

CIK 1731831fmd_0Z09SYRMW5BW25JQDNKHDV59WWManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2016 to Sep 30, 2020, 16 periods

Latest annual · FY2019

Millions
Total revenues
27
Gross profit
24
Operating income
(40)
Net income
(38)
Free cash flow
(32)

Latest quarter · Q3 FY2020

Millions
Total revenues
0
Operating income
(29)
Net income
(30)
Free cash flow
(28)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2016 to FY2019
n/m

Eidos Therapeutics, Inc. financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2019FY2018ChangeSource
Revenue$26.7 million10-K 2020-02-26 · proof
Gross profit$24.2 million10-K 2020-02-26 · proof
Operating income-$40.5 million-$37.8 million10-K 2020-02-26 · proof
Net income-$37.8 million-$40.7 million10-K 2020-02-26 · proof
Cash from operating activities-$31.6 million-$33.3 million10-K 2020-02-26 · proof
Free cash flow-$31.9 million-$33.5 million10-K 2020-02-26 · proof
Total assets$203.8 million$160.1 million+27.3%10-K 2020-02-26 · proof
Total liabilities$32.4 million$5.1 million+534.5%10-K 2020-02-26 · proof
Cash and cash equivalents$191.2 million$157.1 million+21.6%10-K 2020-02-26 · proof
What was Eidos Therapeutics, Inc.'s revenue in fiscal 2019?
Eidos Therapeutics, Inc. reported revenue of $26.7 million for fiscal 2019 (the year ended Dec 31, 2019). Source: the 10-K filed with the SEC on Feb 26, 2020. SEC
What was Eidos Therapeutics, Inc.'s gross profit in fiscal 2019?
Eidos Therapeutics, Inc. reported gross profit of $24.2 million for fiscal 2019 (the year ended Dec 31, 2019). Source: the 10-K filed with the SEC on Feb 26, 2020. SEC
What was Eidos Therapeutics, Inc.'s operating income in fiscal 2019?
Eidos Therapeutics, Inc. reported operating income of -$40.5 million for fiscal 2019 (the year ended Dec 31, 2019), against -$37.8 million the year before. Source: the 10-K filed with the SEC on Feb 26, 2020. SEC
What was Eidos Therapeutics, Inc.'s net income in fiscal 2019?
Eidos Therapeutics, Inc. reported net income of -$37.8 million for fiscal 2019 (the year ended Dec 31, 2019), against -$40.7 million the year before. Source: the 10-K filed with the SEC on Feb 26, 2020. SEC
What was Eidos Therapeutics, Inc.'s cash from operating activities in fiscal 2019?
Eidos Therapeutics, Inc. reported cash from operating activities of -$31.6 million for fiscal 2019 (the year ended Dec 31, 2019), against -$33.3 million the year before. Source: the 10-K filed with the SEC on Feb 26, 2020. SEC
What was Eidos Therapeutics, Inc.'s free cash flow in fiscal 2019?
Eidos Therapeutics, Inc. reported free cash flow of -$31.9 million for fiscal 2019 (the year ended Dec 31, 2019), against -$33.5 million the year before. Source: the 10-K filed with the SEC on Feb 26, 2020. SEC
What are Eidos Therapeutics, Inc.'s total assets?
As of Dec 31, 2019, Eidos Therapeutics, Inc. reported total assets of $203.8 million, against $160.1 million a year earlier (+27.3%). Source: the 10-K filed with the SEC on Feb 26, 2020. SEC
What are Eidos Therapeutics, Inc.'s total liabilities?
As of Dec 31, 2019, Eidos Therapeutics, Inc. reported total liabilities of $32.4 million, against $5.1 million a year earlier (+534.5%). Source: the 10-K filed with the SEC on Feb 26, 2020. SEC
What are Eidos Therapeutics, Inc.'s cash and cash equivalents?
As of Dec 31, 2019, Eidos Therapeutics, Inc. reported cash and cash equivalents of $191.2 million, against $157.1 million a year earlier (+21.6%). Source: the 10-K filed with the SEC on Feb 26, 2020. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1731831&period_type=annual&limit=5"

Information only, not investment advice.